3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Non-Hodgkin
2
Immunoglobulin Light-chain Amyloidosis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Pain
1
Myoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Exanthema
1
Endometritis
1
Amyloidosis, Familial
1
Advanced Malignant Neoplasm
1
AA amyloidosis
1
Interventions
Morphine
6
Analgesia
6
nabiximols
3
Pregabalin
3
Oxycodone
3
Fentanyl
3
ziconotide
2
Surveys and Questionnaires
2
Saline Solution
2
Radiofrequency Ablation
2
Methadone
2
Lidocaine
2
Ketamine
2
Ibandronic Acid
2
Gemcitabine
2
Duloxetine Hydrochloride
2
Docetaxel
2
Botulinum Toxins, Type A
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
tanezumab
1
tandutinib
1
siltuximab
1
resiniferatoxin
1
incobotulinumtoxinA
1
imisopasem manganese
1
fulranumab
1
erenumab
1
cyclobenzaprine
1
caffeine, sodium benzoate drug combination
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pain
×
Doxycycline
×
Clear all
NCT01847976
2019-09-06
OTT12-05
Ottawa Hospital Research Institute
Phase 2
Completed
73 enrolled